Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance.
- befree-2016 importedOn "2016-02-19" NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance.
- NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_assertion wasGeneratedBy ECO_0000203 NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance.
- NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_assertion wasDerivedFrom befree-2016 NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance.
- NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_assertion SIO_000772 15988530 NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance.
- NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_assertion evidence source_evidence_literature NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance.
- NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_assertion description "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance.